S S Engel
Affiliation: Merck Research Laboratories
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisSamuel S Engel
Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
Cardiovasc Diabetol 12:3. 2013..To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators...
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesDebora Williams-Herman
Merck Research Laboratories, Rahway, NJ USA
BMC Endocr Disord 10:7. 2010..The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies...
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitisS S Engel
Merck Research Laboratories, Rahway, NJ 07065 0900, USA
Int J Clin Pract 64:984-90. 2010..0.10 events per 100 patient-years, respectively). Preclinical and clinical trial data with sitagliptin to date do not indicate an increased risk of pancreatitis in patients with T2DM treated with sitagliptin...